Diabetes Care, Vol 21, Issue 4 570-573, Copyright © 1998 by American Diabetes Association

ARTICLES

Postprandial insulin lispro. A new therapeutic option for type 1 diabetic patients

G Schernthaner, W Wein, K Sandholzer, S Equiluz-Bruck, PC Bates and MA Birkett
Department of Internal Medicine, Rudolfstitung Hospital, Vienna, Austria.

OBJECTIVE: For intensified insulin therapy of type 1 diabetes, bolus injection of regular human insulin 30-15 min before a meal is currently recommended. This randomized study is aimed to determine whether insulin lispro (LIS), a new insulin analog with a rapid onset of action, can provide comparable blood glucose (BG) control by injection after the meal. RESEARCH DESIGN AND METHODS: Eighteen type 1 diabetic subjects injected regular insulin (REG) at 40, 20, or 0 min before or LIS at 20 or 0 min before or 15 min after the start of a standardized test meal. BG excursions and area under the curve of BG excursions (AUC) at the six visits were compared by analysis of variance. Hypoglycemic events (BG < or = 2.78 mmol/l) were evaluated in relation to the achieved postprandial BG control. RESULTS: Mean AUC values were 2.00, 2.55, and 3.33 mmol.h.l-1 for REG given 40, 20, and 0 min before the test meal, respectively, and -2.19, -2.15, and 1.98 mmol.h.l-1 for LIS given 20 and 0 min before and 15 min after the start of the test meal, respectively. LIS injected 20 min (-20) or immediately (0) before the meal was significantly more effective in controlling postprandial BG excursion (P < 0.001) than any REG treatment. Postprandial injection of LIS (15) did not compromise postprandial BG control and resulted in less hypoglycemia. REG -40 and LIS -20 were associated with early hypoglycemia, but other hypoglycemic events were equally distributed among groups. CONCLUSIONS: The optimal time for bolus insulin injection was 20 min before the meal for REG and immediately before the meal for LIS. LIS injected immediately after a standard meal provided postprandial BG control at least as good as REG injected from 40 to 0 min before the meal. Postprandial injection of LIS is an attractive new therapeutic option.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				I. Hartman Insulin Analogs: Impact on Treatment Success, Satisfaction, Quality of Life, and Adherence Clin. Med. Res., September 1, 2008; 6(2): 54 - 67. [Abstract] [Full Text] [PDF]

				K. Rave, O. Klein, A. D. Frick, and R. H.A. Becker Advantage of Premeal-Injected Insulin Glulisine Compared With Regular Human Insulin in Subjects With Type 1 Diabetes Diabetes Care, August 1, 2006; 29(8): 1812 - 1817. [Abstract] [Full Text] [PDF]

				F. M Regan and D. B Dunger Use of new insulins in children Arch. Dis. Child. Ed. Pract., August 1, 2006; 91(2): ep47 - ep53. [Full Text] [PDF]

				R. Alemzadeh, J. N. Ellis, M. K. Holzum, E. A. Parton, and D. T. Wyatt Beneficial Effects of Continuous Subcutaneous Insulin Infusion and Flexible Multiple Daily Insulin Regimen Using Insulin Glargine in Type 1 Diabetes Pediatrics, July 1, 2004; 114(1): e91 - e95. [Abstract] [Full Text] [PDF]

				B. Ahmad Review: Pharmacology of insulin The British Journal of Diabetes & Vascular Disease, January 1, 2004; 4(1): 10 - 14. [Abstract] [PDF]

				T. Danne, J. Aman, E. Schober, D. Deiss, J. L. Jacobsen, H. H. Friberg, and L. H. Jensen A Comparison of Postprandial and Preprandial Administration of Insulin Aspart in Children and Adolescents With Type 1 Diabetes Diabetes Care, August 1, 2003; 26(8): 2359 - 2364. [Abstract] [Full Text] [PDF]

				J. Plank, A. Wutte, G. Brunner, A. Siebenhofer, B. Semlitsch, R. Sommer, S. Hirschberger, and T. R. Pieber A Direct Comparison of Insulin Aspart and Insulin Lispro in Patients With Type 1 Diabetes Diabetes Care, November 1, 2002; 25(11): 2053 - 2057. [Abstract] [Full Text] [PDF]

				J. D. Meece and R. K. Campbell Insulin Lispro Update The Diabetes Educator, March 1, 2002; 28(2): 269 - 277. [Abstract] [PDF]